Northern Trust Corp Salarius Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$0.49 - $1.01 $1,080 - $2,227	-2,205 Reduced 3.28%	65,022 $32,000
Q3 2021 Nov 15, 2021	BUY	$0.8 - $1.15 $1,764 - $2,535	2,205 Added 3.39%	67,227 $68,000
Q2 2021 Aug 13, 2021	BUY	$1.02 - $1.52 $13,641 - $20,328	13,374 Added 25.89%	65,022 $69,000
Q1 2021 May 12, 2021	BUY	$1.0 - $3.0 $36,831 - $110,493	36,831 Added 248.57%	51,648 $76,000
Q4 2020 Feb 11, 2021	SELL	$0.65 - $1.34 $4,752 - $9,798	-7,312 Reduced 33.04%	14,817 $13,000
Q3 2020 Nov 16, 2020	BUY	$0.77 - $1.52 $7,192 - $14,198	9,341 Added 73.05%	22,129 $19,000
Q2 2020 Aug 14, 2020	BUY	$0.6 - $1.82 $841 - $2,551	1,402 Added 12.31%	12,788 $17,000
Q1 2020 May 14, 2020	BUY	$0.56 - $3.82 $6,376 - $43,494	11,386 New	11,386 $8,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.25M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.